Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-01-18
2011-01-18
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S012200
Reexamination Certificate
active
07871989
ABSTRACT:
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid as drug carriers, and encapsulating at least one bioactive agent. The nanoparticles are characterized with a positive surface charge configured for promoting enhanced permeability for bioactive agent delivery.
REFERENCES:
patent: 6383478 (2002-05-01), Prokop et al.
patent: 6649192 (2003-11-01), Alonso Fernandez et al.
patent: 6726934 (2004-04-01), Prokop
patent: 2006/0051423 (2006-03-01), Heppe et al.
Lin YH et al. “Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery” Biomacromolecules 2007;8:146-152.
Lin YH et al. “Novel nanoparticles for oral insulin delivery via the paracellular pathway” Nanotechnology 2007;18:1-11.
van der Lubben IM et al. “Chitosan and its derivatives in mucosal drug and vaccine delivery” Euro J Pharma Sci 2001;14:201-207.
Hosny EA et al. “Oral delivery of insulin from enteric-coated capsules containing sodium salicylate” Int J Pharmaceutics 2002;237:71-76.
Thanou M et al. “Chitosan and its derivatives as intestinal absorption enhancers” Adv. Drug Deliv. Rev. 2001;50:S91-S101.
Smith J et al. “Effect of chitosan on epithelial cell tight junctions” Pharmaceutical Research 2004;21:43-49.
Lin YH et al. “Preparation of nanoparticles composed of chitosan/poly-gamma-glutaraldehyde and evaluation of their permeability through Caco-2 cells” Biomacromolecules 2005;6:1104-1112.
Fernandez-Urrusuno R et al. “Enhancement of nasal absorption of insulin using chitosan nanoparticles” Pharmaceutical Research 1999;16:1576-1581.
Mi FL et al. “Oral delivery of peptide drugs using nanoparticles self-assembled by poly(r-glutamic acid) and a chitosan derivative functionalized by trimethylation” Bioconjugate Chem 2008;19:1248-1255.
Minn A et al. “Drug transport into the mammalian brain:the nasal pathway and its specific metabolic barrier” J Drug Targeting 2002;10:285-296.
Vyas TK et al. “Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting” J Pharma Sci 2006;95:570-580.
Hussar P et al. “The glucose transporter GLUT1 and the tight junction protein occludin in nasal olfactory mucosa” Chem Senses 2002;27:7-11.
Ma Z et al. “Uptake of chitosan and associated insulin in Caco-2 cell monolayers:a comparison between chitosan molecules and chitosan nanoparticles” Pharmaceutical Research 2003;20:1812-1819.
Sung Hsing-Wen
Tu Hosheng
GP Medical, Inc.
Monshipouri Maryam
National Tsing Hua University
LandOfFree
Nanoparticles for protein drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nanoparticles for protein drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoparticles for protein drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649412